Adverse events in women switching from olaparib capsules to tablets: retrospective observational study of US claims data

Written by The Evidence Base

In this Publication Perspective, watch lead study author Susana Banerjee (Institute of Cancer Research, London, UK) discuss research she was recently involved in concerning adverse events in women switching from olaparib capsules to tablets.

In this Publication Perspective, originally published in the Video Journal of Biomedicine, lead study author Susana Banerjee (Institute of Cancer Research, London, UK) discusses research she was recently involved in, published in Future Oncology, concerning adverse events in women switching from olaparib capsules to tablets.

In the study, real-world US claims data on patients who have switched from olaparib capsules to tablets were analyzed to provide insight into the tolerability of switching olaparib formulation.

The Video Journal of Biomedicine, published by Future Medicine, provides the missing link between high-quality research information and its intended audience, be that fellow experts, researchers in other fields, students and trainees, or the general public (including patients and caregivers). Through concise, high-quality videos, with the author on screen or via voice-over animation, researchers are able to personally explain their work, highlighting its importance, placing it in context, and discussing future implications.